Besifovir maleate (formerly known as ANA-380 maleate; LB-80380 maleate; PMCDG dipivoxil maleate; Korea Trade name: Besivo) is a reverse transcriptase inhibitor that has been approved in Korea to treat hepatitis B virus (HBV) infection. It is a novel and potent acyclic nucleotide phosphonate with a similar chemical structure to adefovir and tenofovir. Besifovir is a prodrug and an oral nucleotide analogue that inhibits viral replication by incorporation into the viral DNA. Antiviral activity against wild-type virus and virus with drug-resistant mutations was demonstrated in Phase II trials, with significant reduction of viral load in patients treated with LB80380. LB80380 was also shown to be safe and well tolerated.
理化性质和储存条件
Molecular Weight (MW) | 627.58 |
---|
Formula | C26H38N5O11P |
---|
CAS No. | 1039623-01-2 (Besifovir maleate salt); |
---|
Storage | -20℃ for 3 years in powder form |
---|
-80℃ for 2 years in solvent |
Solubility (In vitro) | DMSO: 10 mM |
---|
Water: N/A |
Ethanol: N/A |
Chemical Name | ((((1-((2-amino-9H-purin-9-yl)methyl)cyclopropoxy)methyl)phosphanediyl)bis(oxy))bis(methylene) bis(2,2-dimethylpropanoate) maleate |
---|
Synonyms | LB-80380 maleate; LB 80380; LB80380; ANA-380; AN-380; ANA 380; PMCDG dipivoxil maleate |
---|
SMILES Code | NC1=NC=C2N=CN(CC3(OCP(OCOC(C(C)(C)C)=O)OCOC(C(C)(C)C)=O)CC3)C2=N1.O=C(O)/C=C\C(O)=O |
---|